Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trialDésirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L Pangan, Peter Wung, In-Ho Song
4 July 2022
Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)Yvette Meissner, Anja Strangfeld, Anna Molto, Frauke Forger, Marianne Wallenius, Nathalie Costedoat-Chalumeau, Hilde Bjørngaard, Marion Couderc, René-Marc Flipo, Gaëlle Guettrot-Imbert, Isabell Haase, Bente Jakobsen, Hege Suorza Svean Koksvik, Christophe Richez, Jérémie SellamSee the full list of authors
12 August 2022
Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre studyFabian Proft, Susanne Lüders, Theresa Hunter, Gustavo Luna, Valeria Rios Rodriguez, Mikhail Protopopov, Katharina Meier, Georgios Kokolakis, Kamran Ghoreschi, Denis Poddubnyy
3 August 2022
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritisMurat Torgutalp, Valeria Rios Rodriguez, Ani Dilbaryan, Fabian Proft, Mikhail Protopopov, Maryna Verba, Judith Rademacher, Hildrun Haibel, Joachim Sieper, Martin Rudwaleit, Denis Poddubnyy
13 June 2022
MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working groupXenofon Baraliakos, Mikkel Østergaard, Robert GW Lambert, Iris Eshed, Pedro M Machado, Susanne Juhl Pedersen, Ulrich Weber, Manouk de Hooge, Joachim Sieper, Denis Poddubnyy, Martin Rudwaleit, Désirée van der Heijde, Robert BM Landewé, Walter P Maksymowych
24 May 2022
Factors predicting axial spondyloarthritis among first-degree relatives of probands with ankylosing spondylitis: a family study spanning 35 yearsSjef M van der Linden, Muhammad Asim Khan, Zhixiu Li, Heinz Baumberger, Hermine van Zandwijk, Kazim Khan, Peter M Villiger, Matthew A Brown
11 March 2022
Does biologic therapy impact the development of PsA among patients with psoriasis?Elana Meer, Joseph F Merola, Robert Fitzsimmons, Thorvardur Jon Love, Shiyu Wang, Daniel Shin, Yong Chen, Sharon Xie, Hyon Choi, Yuqing Zhang, Jose U Scher, C T Ritchlin, Joel M Gelfand, Alexis Ogdie
6 October 2021
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trialAnna Molto, Clementina López-Medina, Filip E Van den Bosch, Annelies Boonen, Casper Webers, Emanuelle Dernis, Floris A van Gaalen, Martin Soubrier, Pascal Claudepierre, Athan Baillet, Mirian Starmans-Kool, Anneke Spoorenberg, Peggy Jacques, Philippe Carron, Rik JoosSee the full list of authors
6 May 2021
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?Ulf Lindström, Karin Bengtsson, Tor Olofsson, Daniela Di Giuseppe, Bente Glintborg, Helena Forsblad-d'Elia, Lennart T H Jacobsson, Johan Askling
15 June 2021
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitisZhixiu Li, Xin Wu, Paul J Leo, Erika De Guzman, Nurullah Akkoc, Maxime Breban, Gary J Macfarlane, Mahdi Mahmoudi, Helena Marzo-Ortega, Lisa K Anderson, Lawrie Wheeler, Chung-Tei Chou, Andrew A Harrison, Simon Stebbings, Gareth T JonesSee the full list of authors
20 April 2021